Open Access Critical Evidence Review

The GTPase Rheb is a direct target of the GAP activity of TSC2 and regulates mTOR signaling - Evidence review

The study shows that TSC2 inhibits Rheb, a switch protein that activates mTOR, while Rheb promotes cell growth signals. In the book's paragraph, this clarifies the TSC1/TSC2→Rheb→mTOR cascade. Independent experiments also confirm the inhibition of TSC2 by AKT, but primarily in cellular models; nutrients and energy follow additional controls.

Cite this article
Conte, A. (2026). The GTPase Rheb is a direct target of the GAP activity of TSC2 and regulates mTOR signaling - Evidence review. Life Science Hub Journal. DOI: 10.5281/zenodo.24305369. https://lifesciencehub.info/en/the-gtpase-rheb-is-a-direct-target-of-the-gap-activity-of-tsc2-and-regulates-mtor-signaling
LIFE Science Hub - Journal of Science · 2026 / Nov

DOI 10.5281/zenodo.24305369

Article history
Dates
  • Published 17/11/2026
  • Updated 17/11/2026
Revisions
  1. v1.0 — 17/11/2026 Initial publication of the article.

LIFE Science Hub keeps a record of every published version of the article to ensure editorial transparency. Future revisions will appear here.

Realistic scientific illustration of the TSC2-Rheb-mTOR pathway, with a molecular brake regulating the activation of cell growth signals.
Conceptual representation of the TSC2-Rheb-mTOR pathway: a molecular brake that controls cell growth and protein synthesis. The image visualizes the central biological mechanism discussed in the article, with a realistic and educational approach.

ABSTRACT

The analyzed study examined how the complex formed by TSC1 and TSC2 controls mTOR, a protein that coordinates cell growth and protein synthesis. In the available material, consisting only of the abstract, the authors report that TSC2 acts on Rheb, a small switch protein, promoting its inactivation. When active, Rheb increases the phosphorylation of S6K and 4EBP1, signals linked to protein production; this effect is dependent on mTOR.

In section 4.5 of “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi, the publication contributes primarily to documenting the TSC1/TSC2 → Rheb → mTOR segment. The sentence in the book also includes the inhibition of TSC2 by AKT in response to favorable signals: this specific step is confirmed by independent cellular studies. However, evidence indicates that amino acids and energy status do not regulate mTOR exclusively through TSC2. The chain is therefore well-supported on a mechanistic level, but it does not in itself constitute clinical proof in humans.

Analyzed study

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

Inoki K, Li Y, Xu T, Guan KL

Genes & development, 2003

DOI: 10.1101/gad.1110003

PMID: 12869586

PMCID: PMC196227

The research question was to understand how TSC1/TSC2, a complex of two proteins that limits cell growth, communicates with mTOR. The hypothesis evaluated was that TSC2 exerts its effect through Rheb, a GTPase (a protein that functions as a molecular switch: it is active when it binds GTP and inactive when it converts it into GDP).

The connection to paragraph 4.5 is precise. The book text describes TSC1/TSC2 as a brake on mTOR and states that when AKT is activated by growth signals, this brake is reduced and the anabolic cascade proceeds. The analyzed study documents, above all, the subsequent part of the chain: TSC2 acts as a GAP (a protein that accelerates the switching off of a GTPase) for Rheb; Rheb is located upstream of mTOR and promotes growth signals.

The available material is only the abstract. It does not report a specific experiment in which AKT phosphorylates TSC2, nor does it provide quantitative data on this phosphorylation. Therefore, the publication subject to the Evidence Review does not directly demonstrate the entire insulin → AKT → TSC2 sequence, but it directly supports the TSC2 → Rheb → mTOR segment necessary to understand why the functional inhibition of TSC2 can promote the activation of mTOR.

Materials and methods of the original study

From the only available abstract, it emerges that the authors evaluated the GAP activity of TSC2 towards Rheb and studied the effects of Rheb on downstream mTOR signaling. They analyzed the phosphorylation of S6K and 4EBP1, two proteins used as indicators of the mTOR pathway activity involved in protein synthesis and cell growth.

The authors also verified whether the effect of Rheb depended on mTOR by using rapamycin, a drug that inhibits mTOR, and a dominant-negative form of mTOR, which is a variant designed to hinder the function of the normal protein. The abstract also reports experiments related to nutrient availability and cellular energy status. The number of experiments, cell types, selection criteria, concentrations used, exposure times, statistical analyses, and numerical values are not reported in the available material.

Results

The key finding is that TSC2 showed GAP activity towards Rheb. In simple terms, TSC2 promotes the switching off of Rheb, thereby reducing the ability of this switch protein to transmit a growth signal.

Conversely, Rheb increased the phosphorylation of S6K and 4EBP1. Phosphorylation is a chemical modification that can change a protein's activity; in this case, both signals indicate an increase in the activity of the mTOR pathway linked to protein synthesis. The effect of Rheb was blocked by rapamycin and dominant-negative mTOR. This places Rheb upstream of mTOR: Rheb promotes the activation of the pathway, while mTOR is necessary for the signal to reach S6K and 4EBP1.

The abstract also concludes that Rheb is essential in the regulation of S6K and 4EBP1 in response to nutrients and cellular energy status. However, it does not report absolute values, percentages, P-values, confidence intervals, or experimental details that would allow for an estimation of the effect size. It is therefore not possible to quantify from the available material how large the variation in the observed signals was.

Interpretation

A cell does not activate growth simply because it receives an external signal: it must also verify that it has sufficient resources. The TSC1/TSC2 complex contributes to this regulation by acting as a brake on Rheb. When the brake is active, Rheb remains less active and mTOR receives less stimulation; when the brake is reduced, Rheb can promote mTOR signaling.

The study's specific contribution to the book's narrative is therefore the functional link TSC2 → Rheb → mTOR. This relationship makes it biologically plausible that the inhibition of TSC2 by AKT, described in the paragraph, leaves greater activity for Rheb and allows the anabolic cascade to continue.

However, it is necessary to distinguish between levels of evidence. The data in the abstract concern molecular and cellular mechanisms, not people with insulin exposure or specific nutritional conditions. Furthermore, the available text does not allow us to attribute to the analyzed study the direct demonstration of the inhibitory phosphorylation of TSC2 by AKT. This step requires the support of targeted independent publications.

Independent confirming evidence

Initial confirmation of the AKT → TSC2 pathway comes from biochemical and cellular experiments by Manning and colleagues. The authors identified TSC2 as a target of the PI3K/AKT pathway, where PI3K is an enzyme that transmits signals from growth factors like insulin to the cell. AKT phosphorylated TSC2 in vitro and in cells; furthermore, a non-phosphorylatable variant of TSC2 reduced S6K1 activation. This result supports the direction proposed in the book: AKT activation reduces the inhibitory function of TSC2 and facilitates signaling toward mTOR. This is a mechanistic confirmation in cellular models, not clinical evidence in humans [1].

Garami and colleagues independently reconstructed the central segment of the chain. In cellular experiments, insulin increased Rheb activation through a PI3K-dependent pathway; TSC1/TSC2 inhibited this activation. The authors also showed that Rheb increased S6K1 phosphorylation and that a pathological mutation in the GAP domain of TSC2 failed to effectively turn off Rheb. This study confirms the insulin signal/PI3K → TSC1/TSC2 → Rheb → mTOR signaling sequence, while remaining experimental cellular evidence [2].

A further study clarified a potential detail of the mechanism. In cultured cells, growth signals induced the phosphorylation of TSC2 by AKT and its translocation from the cell membrane to the cytosol, the fluid interior of the cell. This shift reduced the repression of Rheb. The authors observed that the phosphorylation of TSC2 at specific sites did not directly alter its intrinsic GAP activity toward Rheb; instead, it appeared to change its localization and availability to act as a brake. This confirms the general direction of the narrative, but shows that the expression “AKT inhibits TSC2” summarizes a more complex regulatory process [3].

Conflicting evidence

An important distinction concerns the different signals that converge on mTOR. Smith and colleagues studied cells lacking TSC2 and observed that amino acid deprivation still reduced the phosphorylation of S6K1, the S6 protein, and 4E-BP1. Even some effects of cellular stress and energy reduction were maintained in the absence of TSC2. These results indicate that the regulation of mTOR by amino acids and certain stress conditions does not necessarily require TSC2 [4].

This evidence does not contradict the TSC2 → Rheb → mTOR segment documented by the original study, nor the inhibition of TSC2 by AKT in response to growth factors. However, it reduces the generalizability of the statement that groups insulin, amino acids, and energy availability as if they all acted through the same AKT → TSC2 pathway. Insulin and other growth signals have a well-documented pathway through AKT and TSC2; amino acids and energy status also utilize parallel controls.

Summary table of evidence

The table distinguishes the publication subject to the review from the independent research used to confirm or define the narrative passage of the book.

Reference Study type Population or model Main result Direction of evidence Strength of evidence
Original study Cellular and biochemical Experimental models not detailed in the available abstract TSC2 acts as a GAP for Rheb; Rheb increases mTOR-dependent S6K and 4EBP1 signaling. direct confirmation moderate
[1] Cellular and biochemical Mammalian cells and in vitro assays AKT phosphorylates TSC2; a non-phosphorylatable TSC2 reduces signaling to S6K1. direct confirmation moderate
[2] Cellular and biochemical Mammalian cells and recombinant proteins Insulin increases Rheb in a PI3K-dependent manner; TSC1/TSC2 inhibits Rheb and signaling to S6K1. direct confirmation moderate
[3] Cellular Cultured cells AKT phosphorylates TSC2 and promotes its translocation to the cytosol, reducing the repression of Rheb. biologically consistent evidence moderate
[4] Cellular TSC2-deficient cells Amino acid deprivation reduces mTOR signaling even in the absence of TSC2. discordant evidence moderate

Confirmation of the evidence

Claim in the book

In section 4.5, “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi, it is stated that TSC1/TSC2 inhibits mTOR when conditions do not favor growth and that, in the presence of favorable signals, TSC2 is inhibited by AKT-mediated phosphorylation, allowing the anabolic cascade to proceed.

Growth signals, including insulin → PI3K/AKT → reduced function of TSC1/TSC2 → increased Rheb activity → activation of mTOR → protein synthesis and cell growth signals

The publication subject to the Evidence Review was used in the book to support the following passage: the TSC1/TSC2 complex limits mTOR activation because TSC2 turns off Rheb, a protein located upstream of mTOR; when the brake exerted by TSC1/TSC2 is reduced, Rheb can promote the continuation of the anabolic signal.

The correspondence with the paragraph is biologically precise. The publication subject to the Evidence Review documents the TSC2 → Rheb → mTOR segment, which constitutes the necessary molecular link between the TSC1/TSC2 complex and the activation of growth signals. In “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi, the reference is therefore functional to explain why the inhibition of TSC2 allows the cascade toward mTOR to continue.

Independent evidence reinforces the entire sequence without attributing to a single study what requires multiple steps. Cellular studies show that AKT can phosphorylate TSC2 and reduce its ability to contain the downstream signal [1,3]. Another experimental line confirms that insulin, through PI3K, promotes the activation of Rheb and that TSC1/TSC2 acts as its brake [2]. The chain is therefore convergent at the molecular and cellular level.

However, the formulation must remain circumscribed. The available data do not demonstrate that amino acids, energy, and insulin always and exclusively use the same circuit. In particular, the mTOR response to amino acid deprivation can persist even without TSC2 [4].

Overall level of confirmation

MECHANISTIC CONFIRMATION

The TSC1/TSC2 → Rheb → mTOR pathway is directly documented by the analyzed publication and confirmed by independent experimental studies. The functional inhibition of TSC2 by AKT is also supported in cellular models. However, the evidence is primarily molecular and cellular, and the chain does not equate to direct clinical proof in humans.

Conclusions

The study analyzed directly supports that TSC2 inhibits Rheb and that Rheb promotes mTOR-dependent signals associated with cell growth. This is the segment of the book's narrative that is effectively documented by the available publication.

Independent literature confirms that AKT can reduce TSC2 function and that the TSC1/TSC2 complex limits Rheb activation in response to growth signals. The chain is therefore well-supported at a mechanistic level. Caution remains necessary when considering amino acids, energy, and insulin as identical regulators, as mTOR integrates parallel pathways that are dependent on the biological context.

Overall assessment

The narrative is confirmed at a mechanistic level: TSC1/TSC2 limits Rheb and mTOR, while AKT can reduce this brake in cellular models. The connection to the book's paragraph is well-supported, but generalization to nutritional and energy signals requires caution, as it involves additional regulatory pathways.

References

[1] Identification of the Tuberous Sclerosis Complex-2 Tumor Suppressor Gene Product Tuberin as a Target of the Phosphoinositide 3-Kinase/Akt Pathway

Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC, 2002

Molecular Cell

[2] Insulin Activation of Rheb, a Mediator of mTOR/S6K/4E-BP Signaling, Is Inhibited by TSC1 and 2

Garami A, Zwartkruis FJT, Nobukuni T, Joaquin M, Roccio M, Stocker H, et al., 2003

Molecular Cell

[3] Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning

Cai SL, Tee AR, Short JD, Bergeron JM, Kim J, Shen J, et al., 2006

The Journal of Cell Biology

[4] The Tuberous Sclerosis Protein TSC2 Is Not Required for the Regulation of the Mammalian Target of Rapamycin by Amino Acids and Certain Cellular Stresses

Smith EM, Finn SG, Tee AR, Browne GJ, Proud CG, 2005

Journal of Biological Chemistry

Editorial note

Artificial Intelligence was used solely as a tool to support editorial and documentary work. All content, interpretations, bibliographic citations and conclusions have been verified, reviewed and approved by the author, who assumes full scientific responsibility for them.

The manuscript was also subject to independent peer review prior to publication.

To ensure maximum transparency, the article's complete history — including the dates of submission, review, acceptance and publication, as well as information on the peer review process — is available on the dedicated Article History page.